ICCM
IceCure Medical Ltd·Healthcare
0.32
4.912%(−0.02)
Market ClosedLast Updated: — ET
52W L: $0.2852W H: $1.40
ICCM NEWS
defenseworld.net
Mar 29
Reviewing IceCure Medical (NASDAQ:ICCM) and Pediatrix Medical Group (NYSE:MD)
Pediatrix Medical Group (NYSE: MD - Get Free Report) and IceCure Medical (NASDAQ: ICCM - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability. Risk and Volatility Pediatrix Medical Group
defenseworld.net
Mar 27
Head-To-Head Analysis: Biocorrx (OTCMKTS:BICX) and IceCure Medical (NASDAQ:ICCM)
IceCure Medical (NASDAQ: ICCM - Get Free Report) and Biocorrx (OTCMKTS:BICX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership. Risk and Volatility IceCure Medical has a beta
prnewswire.com
Mar 26
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement
CAESAREA, Israel, March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8,000,000 ordinary shares at a purchase price of $0.50 per share in a registered direct offering.
prnewswire.com
Mar 25
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study population Full analysis of results to be presented at European Conference of Interventional Oncology 2026 in Basel, Switzerland Data supports broader commercial adoption of ProSense® as a minimally invasive treatment for small renal masses in markets where it is approved for kidney cancer, including the U.S. and Europe CAESAREA, Israel, March 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced positive top-line results from its ICESECRET clinical trial of ProSense® for the treatment of small renal masses ("SRMs") in kidney cancer patients.
prnewswire.com
Mar 24
IceCure Appoints Meir Peleg as Chief Financial Officer
Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companies IceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the appointment of Mr.
defenseworld.net
Mar 22
Analyzing IceCure Medical (NASDAQ:ICCM) & Danaher (NYSE:DHR)
Danaher (NYSE: DHR - Get Free Report) and IceCure Medical (NASDAQ: ICCM - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk. Institutional and Insider Ownership 79.1% of Danaher shares are
